Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors

Trial Profile

Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Axitinib (Primary) ; Everolimus (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms EVAX
  • Most Recent Events

    • 05 Sep 2017 Results published in the European Journal of Cancer.
    • 22 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2013 Planned End Date changed from 1 Feb 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top